Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole glutamate challenge study in adults with 22q11 deletion syndrome
NL-OMON47173Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of riluzole in Velocardiofacial syndrome (VCFS) (2 arms), sponsored by Maastricht University. Primary endpoint: Glutamate concentrations after riluzole and placebo. Started Mar 2015; status: active, not recruiting.
02
Drugs
riluzole
03
Conditions
Velocardiofacial syndrome (VCFS)
Beyond the preview
Go deeper on NL-OMON47173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47173.